Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma

BACKGROUND: Cholangiocarcinoma is an aggressive tumor with poor prognosis. Most of the cases are not available for surgery at the stage of the diagnosis and the best clinical practice chemotherapy results in about 12-month median survival. Several tyrosine kinase inhibitors (TKIs) are currently unde...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Exp Hematol Oncol
Main Authors: Poddubskaya, Elena V., Baranova, Madina P., Allina, Daria O., Smirnov, Philipp Y., Albert, Eugene A., Kirilchev, Alexey P., Aleshin, Alexey A., Sekacheva, Marina I., Suntsova, Maria V.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6127913/
https://ncbi.nlm.nih.gov/pubmed/30202637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0113-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados